ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
9 announcements with these filters
SMS Pharmaceuticals disclosed two market sell trades by Designated Person NVV Satyanarayana totalling ₹0.14 Crore. The PIT Reg 7(2) intimation involves a non-promoter designated person.
SMS Pharmaceuticals Limited has scheduled its 38th Annual General Meeting for September 29, 2026. Key agenda items include dividend declaration, management re-appointments, and approval of material related party transactions.
SMS Pharmaceuticals Limited has released its Annual Report and Notice for the 38th Annual General Meeting scheduled for September 29, 2026. The company reported FY26 revenue of ₹887 Crore.
CARE Ratings Limited has reaffirmed or revised the credit ratings for SMS Pharmaceuticals Limited's bank facilities. The review covers the company's long-term and short-term credit facilities.
SMS Pharma reported Q1FY27 revenue of ₹207 Cr (+6% YoY) with stable EBITDA margins at ~20%. Strategy focuses on high-value APIs and peptide R&D.
SMS Pharmaceuticals Ltd reported revenue from operations of ₹207 Cr (+5.6% YoY) and net profit of ₹20.9 Cr (+2.0% YoY) for Q1 FY27.
SMS Pharma delivered FY26 revenue of ₹887cr (+13%) and PAT of ₹102cr (+47%). Strategy focuses on backward integration and high-margin API expansion.
SMS Pharma reported strong FY26 performance with PAT reaching ₹102 crore (up 48% YoY) and EBITDA margins expanding to 19%.
SMS Pharmaceuticals Ltd reported revenue from operations of ₹237.9 Cr (-4.1% YoY) and net profit of ₹32.7 Cr (+61.1% YoY) for Q4 FY26.